This invention provides a nanomaterial for relieving
inflammation and pain in tendinopathy and its preparation method, relating to the field of
biomedical technology. The nanomaterial comprises decellularized
tendon DTM and
hybrid membrane vesicles (MSM) of macrophages and
nerve cells. The aforementioned nanomaterial for relieving
inflammation and pain in tendinopathy includes decellularized
tendon DTM and
hybrid membrane vesicles (MSM) of macrophages and
nerve cells. Combining these two components yields DTM-MSM, which regulates the proliferation and differentiation of
tendon stem cells, modulates the local
immune microenvironment, and relieves pain. It can improve
inflammation and pain in tendinopathy and accelerate the repair of damaged tendons. In other words, DTM-MSM can not only alleviate the pathophysiological changes in tendinopathy but also rapidly improve the main clinical symptoms of tendinopathy, such as pain, swelling, and functional limitation, thus overcoming the current shortcomings of tendinopathy treatments, including slow
onset of action,
poor compliance, significant side effects, and unclear
efficacy.